The Canadian market access and reimbursement environment is in an era of unprecedented change. HTA bodies are transforming their organizations to make review processes more efficient and give Canadians faster access to new drugs (e.g., Target Zero, time-limited recommendations, streamlined economic reviews, rolling reviews). At the same time, Canadian drug prices continue to be regulated under PMPRB’s interim guidelines, the pCPA is increasingly leveraging the Targeted Negotiation Process, and the federal government has taken the first steps toward National Pharmacare. This rapidly changing environment brings both opportunities and potential threats for those seeking to commercialize innovative therapies in Canada. More than ever, market access success depends on having the right partner.
EVERSANA is a leading provider of global HEOR services with a proven track record in all aspects of Canadian HTA, market access and price negotiations. With unparalleled knowledge of the Canadian reimbursement environment, as well as payer and HTA perspectives, we provide exceptional strategic advice, customer service, responsiveness and project management (including HTA touch point management).
We differentiate ourselves from our competitors by leveraging:
- A team of more than 150 market access and HEOR professionals, including former senior CDA-AMC staff
- Thought leaders in evidence synthesis (SLR/ITC)
- A world-class economic modeling team
- Experts in biostatistics and RWD/RWE
- A dedicated team of advocacy and stakeholder relations experts
- Over 20 years of experience on hundreds of Canadian submissions in virtually every therapeutic area, including drugs for rare diseases as well as cell and gene therapies.
Four recent examples demonstrate the value of working with a full-service Canadian market access partner that can leverage its technical expertise in modeling and SLR/ITC, as well as capabilities in advocacy, to the benefit of its clients.
| The Challenge | The EVERSANA Difference |
|---|---|
| The client was submitting a drug in a new therapeutic class for a life-threatening disease to CDA-AMC. The client wanted to submit it as early as possible to ensure a recommendation would be issued as close as possible to NOC. Three months prior to submission, the global health economic model was found to have structural limitations requiring significant reprogramming to meet CDA-AMC requirements. The client’s team (and its global vendor) did not have the capacity to make the revisions in a timely manner. | The EVERSANA economic modeling team expertly and expeditiously completed the necessary reprogramming. The team also worked with the client’s global PE vendor to assist in making parallel changes to the model being submitted to NICE and assisted with QC of the global model. Submissions to CDA-AMC proceeded without delay, and the enhancements made to the global model benefited the NICE submission. |
| The client was planning to submit a new drug in an established therapeutic area. Through interviews with Canadian clinicians, a commonly used off-label comparator was identified that would be considered relevant by Canadian HTA bodies. This comparator was not included in the global health economic model or the ITC. | The EVERSANA evidence synthesis team conducted a rapid SLR and feasibility assessment, which showed that an ITC of the off-label comparator was not possible given the available clinical evidence. The CDA-AMC accepted the results of the feasibility assessment and agreed that the comparator could not be included in the economic model. Submissions to the CDA-AMC proceeded on schedule. |
| The client was submitting a drug to Canadian HTA bodies but did not have access to a global SLR/ITC or economic model that could be adapted for Canada. | The EVERSANA evidence synthesis and economic modeling teams were able to develop both the SLR/ITC and economic model from scratch (along with all other required submission components) in a seamless and cost-effective manner, resulting in timely, high-quality submissions to Canadian HTA bodies. |
| The client was planning to submit a drug for a rare disease for which there were two established therapeutic options. The new drug had a similar efficacy and safety profile as the comparators, yet offered a more convenient dosing schedule and mode of administration. The market access landscape and reimbursement strategy identified that there were no established patient organizations for this specific rare disease; there was a substantial risk that the drug could receive a negative HTA recommendation if unmet need from the patient perspective was not provided. | The EVERSANA advocacy team identified and helped mobilize several relevant patient groups, ensuring that they could participate in the HTA patient input process. This ensured that the patient voice was adequately captured and that the value of greater patient convenience was recognized. |
Meet our team at CDA_AMC to discuss our outstanding full-service market access offerings and how we can help maximize the market potential of your product in our rapidly changing Canadian reimbursement environment.
Author
Christine is a former hospital-based clinician who has worked as a market access consultant to the Canadian pharma industry for over 15 years. She has substantial knowledge of the Canadian reimbursement environment, having gained…
Sumeet Singh is a Senior Director at EVERSANA where he leads HEOR projects for Canadian and global pharmaceutical clients. Prior to joining EVERSANA, Sumeet held various leadership positions at the Canadian Agency for Drugs…